Ipsen S.A. Sponsored ADR (I7G0)

Overview

Ipsen S.A. is a globally recognized biopharmaceutical company, with operations spanning worldwide. Established in 1929 and headquartered in Boulogne-Billancourt, France, the company has cemented its reputation as a leader in the development and commercialization of innovative drugs. Ipsen's key therapeutic focus areas include oncology, neuroscience, and rare diseases, addressing some of the most challenging medical conditions with cutting-edge research and developmental breakthroughs. Through a robust product pipeline and a dedication to improving patient outcomes, Ipsen S.A. demonstrates a relentless pursuit of therapeutic advancements to meet unmet medical needs.

Products and Services

• Cabometyx + Atezolizumab: Currently in phase III clinical trial targeting second line metastatic castration-resistant prostate cancer. This combination therapy showcases Ipsen's dedication to advancing oncology treatment options.
• Lenalidomide and Rituximab and Taverik: Engaged in phase III trials focusing on second line follicular lymphoma, highlighting the company’s efforts in combating haematological malignancies.
• Bylvay: In phase III for treating biliary atresia, Bylvay represents Ipsen’s commitment to addressing rare and serious liver conditions in pediatric populations.
• Dysport: Undergoing phase III clinical trials for chronic and episodic migraine, Dysport illustrates Ipsen’s innovations in the neurosciences realm, offering potential relief to millions suffering from debilitating migraine conditions.
• Fidrisertib: Targeting fibrodysplasia ossificans progressiva in a phase II clinical trial, positioning Ipsen at the forefront of research in rare skeletal disorders.
• Elafibranor: This compound is in phase II for primary sclerosing cholangitis, further showcasing Ipsen's ongoing efforts to treat rare liver diseases.
• IPN60250, IPN10200, IPN60210, and IPN60260: Ranging from phase II to I trials, these products demonstrate Ipsen's enduring commitment to expanding its portfolio in aesthetics, therapeutics, multiple myeloma, and viral cholestatic diseases, respectively.
• Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik: These are among Ipsen's flagship oncology products, addressing a variety of cancers and showcasing the breadth of Ipsen’s impact in oncology.
• Dysport (Neurosciences): Apart from its application in migraine, Dysport serves a vital role in other neurological conditions, emphasizing Ipsen’s broader commitment to neuroscience.
• Bylvay, NutropinAq, Increlex, and Sohonos (Rare Diseases): Serving patients with rare diseases, these products highlight Ipsen’s dedication to providing solutions for some of the most complex and uncommon medical conditions.